Sold as Vaprisol, Vaprisol In 5% Dextrose In Plastic Container. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Conivaptan Hydrochloride (sold as Vaprisol, Vaprisol In 5% Dextrose In Plastic Container), first approved Dec 29, 2005, with 0 new uses approved and 0 published complete response letters.
| Dec 29, 2005 | Vaprisol, Vaprisol In 5% Dextrose In Plastic ContainerNDA 21697 · New molecular entity | Apotex | 4 | Marketed |
| Feb 28, 2007 | VaprisolNDA 22016 · TYPE 6 | Cumberland Pharms | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Apotex